Q-omics provides the consensus-scored ZNF215 profile across patient tissues and cancer cell-line models. ZNF215 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ZNF215 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ZNF215 RNA expression shows 16,247 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, KICH, and UVM as cancer lineages where ZNF215 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF215 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF215 survival associations across molecular data types. ZNF215 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF215 RNA expression–survival associations across cancer types. High ZNF215 expression shows unfavorable associations in STAD, LIHC, THCA and LAML, but favorable associations in READ and SCLC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for ZNF215 RNA expression.
This table summarizes ZNF215 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF215. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF215 shows lower tumor expression in KICH and BRCA and higher tumor expression in COAD, LUAD, CHOL and HNSC. The KICH box plot shows higher ZNF215 RNA expression in normal versus tumor tissue (log2 FC = −1.332, t-test p < 0.001).
This table shows molecular features associated with ZNF215 in patient tissues and cancer cell lines. In patient samples, ZNF215 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF215 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
